Privately held Acceleron Pharma Inc. entered a potential $498 million deal with Basingstoke, UK-based Shire plc to develop drugs for rare muscle disorders, including its Phase II candidate for Duchenne's muscular dystrophy (DMD). (BioWorld Today) Read More
